194 related articles for article (PubMed ID: 25384122)
1. Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer.
Nie W; Xu MD; Gan L; Huang H; Xiu Q; Li B
Lab Invest; 2015 Jan; 95(1):56-64. PubMed ID: 25384122
[TBL] [Abstract][Full Text] [Related]
2. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
Bao P; Yokobori T; Altan B; Iijima M; Azuma Y; Onozato R; Yajima T; Watanabe A; Mogi A; Shimizu K; Nagashima T; Ohtaki Y; Obayashi K; Nakazawa S; Bai T; Kawabata-Iwakawa R; Asao T; Kaira K; Nishiyama M; Kuwano H
Ann Surg Oncol; 2017 Dec; 24(13):4017-4024. PubMed ID: 28933054
[TBL] [Abstract][Full Text] [Related]
3. Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
Li J; Hu G; Kong F; Wu K; Song K; He J; Sun W
Pathol Oncol Res; 2015 Sep; 21(4):1013-20. PubMed ID: 25791566
[TBL] [Abstract][Full Text] [Related]
4. Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors.
Shimizu K; Goto Y; Kawabata-Iwakawa R; Ohtaki Y; Nakazawa S; Yokobori T; Obayashi K; Kawatani N; Yajima T; Kaira K; Mogi A; Hirato J; Nishiyama M; Shirabe K
Ann Thorac Surg; 2019 Jul; 108(1):235-243. PubMed ID: 30910656
[TBL] [Abstract][Full Text] [Related]
5. Increased stathmin correlates with advanced stage and poor survival of non-small cell lung cancer.
Rong B; Nan Y; Liu H; Gao W
Cancer Biomark; 2017; 19(1):35-43. PubMed ID: 28282798
[TBL] [Abstract][Full Text] [Related]
6. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
7. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Stathmin 1 correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma.
Ni PZ; He JZ; Wu ZY; Ji X; Chen LQ; Xu XE; Liao LD; Wu JY; Li EM; Xu LY
Oncol Rep; 2017 Dec; 38(6):3608-3618. PubMed ID: 29039594
[TBL] [Abstract][Full Text] [Related]
9. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
Zou ZQ; Du YY; Sui G; Xu SN
Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
[TBL] [Abstract][Full Text] [Related]
10. Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma.
He X; Liao Y; Lu W; Xu G; Tong H; Ke J; Wan X
Tumour Biol; 2016 Jul; 37(7):9951-8. PubMed ID: 26815505
[TBL] [Abstract][Full Text] [Related]
11. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle-related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in non-small-cell lung cancer.
Li W; Zheng G; Xia J; Yang G; Sun J; Wang X; Wen M; Sun Y; Zhang Z; Jin F
Cancer Sci; 2018 Apr; 109(4):1012-1023. PubMed ID: 29397041
[TBL] [Abstract][Full Text] [Related]
14. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN
Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.
Xu CH; Sheng ZH; Hu HD; Hao KK; Wang QB; Yu LK
Tumour Biol; 2014 Sep; 35(9):8673-8. PubMed ID: 24870591
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
[TBL] [Abstract][Full Text] [Related]
18. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.
Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC
Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015
[TBL] [Abstract][Full Text] [Related]
19. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
Mlak R; Krawczyk P; Ciesielka M; Homa I; Powrózek T; Prendecka M; Kozioł P; Milanowski J; Małecka-Massalska T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):621-9. PubMed ID: 26220844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
